SLC5A2 and kidney disorder: Similarly, SGLT2 inhibitors have emerged as a promising antidiabetic drug that confers additional benefits to alleviate progressive kidney disease, whose renal action is purportedly attributed in part to afferent arteriolar vasoconstriction due to enhanced TGF [28–30].